The estimated Net Worth of Mary Ann Gray is at least $1.76 Million dollars as of 10 December 2021. Mary Gray owns over 967 units of Sarepta Therapeutics Inc stock worth over $1,207,251 and over the last 20 years he sold SRPT stock worth over $0. In addition, he makes $556,716 as Independent Director at Sarepta Therapeutics Inc.
Mary has made over 9 trades of the Sarepta Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 967 units of SRPT stock worth $124,153 on 10 December 2021.
The largest trade he's ever made was exercising 132,839 units of Sarepta Therapeutics Inc stock on 7 April 2016 worth over $176,676. On average, Mary trades about 2,983 units every 47 days since 2005. As of 10 December 2021 he still owns at least 9,403 units of Sarepta Therapeutics Inc stock.
You can see the complete history of Mary Gray stock trades at the bottom of the page.
Dr. Mary Ann Gray Ph.D. serves as Independent Director of the Company. Dr. Gray has served as a member of our Board since December 2010. She also serves as a member of our compensation committee and as a member of our nominating and corporate governance committee. Most recently, from 2010 to 2018, Dr. Gray served as a member of the Board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. She served as a member of the compensation committee of Senomyx from May 2011 to November 2018, as the Chair of the Board and a member of the audit committee from May 2016 to November 2018, and as Lead Director from May 2017 to November 2018. Dr. Gray also served as a member of the Board and audit committee Chair of Juniper Pharmaceuticals, a women’s health company, from April 2016 to August 2018. From November 2014 to December 2016, she served as a Board member of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. She served as the Chair of the audit committee of Tetralogic from March 2015 to December 2016. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016, and served as a member of the audit committee from 2005 to 2016 and as a member of the compensation committee from 2010 to 2016. She served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016, from 2001 to 2016, serving as a Lead Director from 2008 to 2016, a member of the audit committee from 2004 to 2012, a member of the nominating and corporate governance committee from 2001 to 2016, and Chair of the compensation committee from 2012 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm.
As the Independent Director of Sarepta Therapeutics Inc, the total compensation of Mary Gray at Sarepta Therapeutics Inc is $556,716. There are 14 executives at Sarepta Therapeutics Inc getting paid more, with Gilmore O'Neill having the highest compensation of $5,168,110.
Mary Gray is 67, he's been the Independent Director of Sarepta Therapeutics Inc since 2018. There are 1 older and 13 younger executives at Sarepta Therapeutics Inc. The oldest executive at Sarepta Therapeutics Inc is Hans Wigzell, 82, who is the Independent Director.
Mary's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.
Over the last 12 years, insiders at Sarepta Therapeutics Inc have traded over $58,674,663 worth of Sarepta Therapeutics Inc stock and bought 827,614 units worth $49,516,406 . The most active insiders traders include John C Martin, Richard Barry, and M Kathleen Behrens. On average, Sarepta Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,737,275. The most recent stock trade was executed by Ian Michael Estepan on 30 August 2024, trading 5,985 units of SRPT stock currently worth $822,100.
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
Sarepta Therapeutics Inc executives and other stock owners filed with the SEC include: